Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

Inclusion criteria

• . Subject is at least 21 years of age;
• . Subject has a diagnosis of diabetic neuropathic pain of the feet determined by the subject's primary care physician or related health care provider.
• . Subject has a mean pain scale score of ≥ 5 recorded in the 7 days prior to randomization.
• . If female, the subject is postmenopausal (\> 1 year), surgically sterile (\> 3 months), had a hysterectomy, or is currently using 2 effective forms of birth control.
• . Subject has not taken marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD for at least 14 days prior to this study, and agrees to not take marijuana (cannabis) in any form, chemicals or extracts or foods or beverages or topical creams, lotions, gels, patches containing marijuana (cannabinoids, or and cannabis derivatives) including synthetic marijuana and/or CBD while participating in this study.
• . If subject is currently taking gabapentin, pregabalin, or duloxetine, subject must be willing to and completes a 7-day washout of these medications prior to randomization.
• . Subject has not taken any NSAIDs and/or acetaminophen for at least 2 days prior to randomization.
• . Subject is willing to provide his/her written informed consent to participate in the study as stated in the informed consent document.

Exclusion criteria